skip to main content
UK Health Security Agency

SKMES-1-Adr

SKMES-1-Adr

Catalogue No.

20082611

Cell Line Name

SKMES-1-Adr

Cell Line Description

Resistant variant of SKMES-1 developed by selection in increasing concentrations of Adriamycin. The parental cell line being derived from the pleural effusion of a 65 year old Caucasian male with squamous cell carcinoma of the lung.

Established by exposure to Adriamycin final concentration 0.43 µg/ml.

Characteristics

Tissue of Origin

Derived from the pleural effusion with squamous cell carcinoma of the lung.

Morphology

Epithelial

DNA profile (STR Profile)

Amelogenin: X,Y
CSF1PO: 12
D3S1358: 16
D5S818: 11
D7S820: 8
D8S1179: 13, 14
D13S317: 11
D16S539: 13
D18S51: 17
FGA: 20, 24
Penta D: 12, 13
Penta E: 5, 11
TH01: 6, 9.3
TPOX: 8
vWA: 14

Karyotype

2n=46

Disease

Squamous Cell Carcinoma

Culture Conditions

Cell Type

Squamous cell carcinoma

Subculture Routine

Incubate cells at 37oC, 5% CO2, in vented tissue culture flasks. Seed cells between 2-4x10e4 cells/cm² and feed twice a week with fresh media.

Adriamycin at a final concentration of 0.43 µg/ml can be added after the first passage once cell growth has been established.

Culture Medium

EMEM (EBSS) + 2mM L-Glutamine + 10% Foetal Bovine Serum (FBS) + 1% NEAA + 1% NaP

 

Adriamycin at a final concentration of 0.43 µg/ml can be added after the first passage and removed before cryopreservation.

 

Freeze in 10% DMSO + 90% FBS.

Growth Mode

Adherent

Additional Info

Depositor

Depositor: Martin Clynes. National Institute for Cellular Biotechnology, Dublin City University. Originator: Alice Redmond (1990) National Institute for Cellular Biotechnology, Dublin City University

Country of Origin

Ireland

GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Alice Redmond (1991). Multiple Drug Resistance in human tumour cell lines. (1991). PhD thesis, Dublin City University.

Bibliography

Cleary, Irene (1995) Drug accumulation studies in multiple drug resistant human cell lines. PhD thesis, Dublin City University.

Cleary I, Doherty G, Moran E, Clynes M. (1997). Biochem Pharmacol. May 15;53(10):1493-502.

Gravies R, Davis R, Owen P, Clynes M, Cleary I, O'Beirne G. J. (1997). Biochem Biophys Methods. Jun 9;34(3):177-87. PMID:9314096

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: SKMES-1-Adr (ECACC 20082611).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.